Axa S.A. Raises Stock Holdings in Pfizer Inc. $PFE

Axa S.A. boosted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 13.3% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,518,659 shares of the biopharmaceutical company’s stock after acquiring an additional 296,001 shares during the quarter. Axa S.A.’s holdings in Pfizer were worth $61,052,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the business. GKV Capital Management Co. Inc. bought a new position in shares of Pfizer in the first quarter worth about $27,000. Curio Wealth LLC boosted its position in Pfizer by 36,600.0% in the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 1,098 shares during the period. Bayforest Capital Ltd bought a new position in Pfizer in the 1st quarter worth about $28,000. Harbor Asset Planning Inc. purchased a new position in shares of Pfizer during the second quarter worth approximately $29,000. Finally, Howard Hughes Medical Institute bought a new stake in shares of Pfizer during the second quarter valued at approximately $30,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of PFE opened at $25.36 on Wednesday. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. The firm has a market cap of $144.16 billion, a PE ratio of 14.74 and a beta of 0.46. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.69. The stock has a fifty day moving average price of $25.21 and a 200-day moving average price of $24.73.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.08. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.The company had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 7th were paid a $0.43 dividend. The ex-dividend date was Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a yield of 6.8%. Pfizer’s dividend payout ratio (DPR) is 100.00%.

Analyst Ratings Changes

Several research firms have commented on PFE. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Morgan Stanley cut their price target on Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research note on Friday, October 10th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Bank of America raised their target price on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Finally, Scotiabank assumed coverage on shares of Pfizer in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $28.39.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.